Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Novartis has agreed to acquire Avidity Biosciences for $12 billion in cash, representing a 46% premium, with the transaction expected to close in H1 2026. This strategic move aims to significantly strengthen Novartis's neuroscience franchise by integrating Avidity's late-stage programs for genetic neuromuscular diseases, including DM1, FSHD, and DMD, along with its proprietary muscle-directed Antibody Oligonucleotide Conjugates (AOCs™) platform. The acquisition is projected to unlock multi-billion-dollar opportunities with product launches before 2030 and is expected to raise Novartis's 2024-2029 sales CAGR from +5% to +6%, contingent on Avidity first separating its early-stage precision cardiology programs into a new company.

Analysis

Novartis announced its intent to acquire Avidity Biosciences for $12 billion in cash, valuing Avidity at $72.00 per share, a 46% premium over its October 24, 2025 closing price. This strategic acquisition is set to significantly bolster Novartis's neuroscience franchise and advance its xRNA strategy by integrating Avidity's late-stage programs and its proprietary Antibody Oligonucleotide Conjugates (AOCs™) platform. The transaction is expected to close in H1 2026, contingent on Avidity separating its early-stage precision cardiology programs into a new entity, SpinCo.

The acquisition brings three late-stage programs targeting genetic neuromuscular diseases, including DM1, FSHD, and DMD, which currently lack disease-modifying therapies. Avidity's AOC platform offers a differentiated RNA-targeting delivery mechanism, combining monoclonal antibodies with oligonucleotides for precise muscle cell delivery. This technology is anticipated to create an industry-leading pipeline and complement Novartis's existing expertise in spinal muscular atrophy.

Financially, Novartis projects the acquisition will raise its expected 2024-2029 sales CAGR from +5% to +6%, contributing to mid-single-digit long-term growth and unlocking multi-billion-dollar opportunities with planned product launches before 2030. Avidity shareholders will receive the cash consideration plus a distribution of SpinCo shares, or pro-rata cash from SpinCo asset sales. The deal's success hinges on customary closing conditions, including regulatory and stockholder approvals, and the successful spin-off of Avidity's cardiology assets.

Key Decisions for Investors

• Novartis (NVS) investors should evaluate the long-term growth prospects from the enhanced neuroscience pipeline and the integration risks associated with a $12 billion acquisition.
• Avidity (RNA) shareholders are set to realize a substantial 46% premium and will also receive shares in the newly formed SpinCo, offering potential future value in precision cardiology.
• All investors should closely monitor the transaction's progress, particularly the successful separation of SpinCo and the timely receipt of regulatory approvals, as these are critical conditions for closing in H1 2026.